Username

Password

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Laurie Owen-Schaub

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Anatomy

Living Beings

Mice

Physiology

Disorders

Phenomena

Ultraviolet Rays

Procedures

Flow Cytometry

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Guzmán Esther A; Langowski John L; De Guzman Ariel; Muller H Konrad; Walker Ameae M; Owen Laurie B
S179D prolactin diminishes the effects of UV light on epidermal gamma delta T cells.
Peter Marcus E; Budd Ralph C; Desbarats Julie; Hedrick Stephen M; Hueber Anne-Odile; Newell M Karen; Owen Laurie B; Pope Richard M; Tschopp Juerg; Wajant Harald; Wallach David; Wiltrout Robert H; Zörnig Martin; Lynch David H
The CD95 receptor: apoptosis revisited.
Ma Lisa J; Guzmán Esther A; DeGuzman Ariel; Muller H Konrad; Walker Ameae M; Owen Laurie B
Local cytokine levels associated with delayed-type hypersensitivity responses: modulation by gender, ovariectomy, and estrogen replacement.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Laurie Owen-Schaub (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2008: Guzmán Esther A; Langowski John L; De Guzman Ariel; Muller H Konrad; Walker Ameae M; Owen Laurie B
S179D prolactin diminishes the effects of UV light on epidermal gamma delta T cells.
Molecular and cellular endocrinology 2008;280(1-2):6-12.
2007: Peter Marcus E; Budd Ralph C; Desbarats Julie; Hedrick Stephen M; Hueber Anne-Odile; Newell M Karen; Owen Laurie B; Pope Richard M; Tschopp Juerg; Wajant Harald; Wallach David; Wiltrout Robert H; Zörnig Martin; Lynch David H
The CD95 receptor: apoptosis revisited.
Cell 2007;129(3):447-50.
2007: Ma Lisa J; Guzmán Esther A; DeGuzman Ariel; Muller H Konrad; Walker Ameae M; Owen Laurie B
Local cytokine levels associated with delayed-type hypersensitivity responses: modulation by gender, ovariectomy, and estrogen replacement.
The Journal of endocrinology 2007;193(2):291-7.
2006: Doherty Sean D; Ni Xiao; Doherty Christy B; Jones Dan; Zhao Xing; Owen Laurie B; Duvic Madeleine
Abnormal expression of interleukin-23 in mycosis fungoides/Sézary syndrome lesions.
Archives of dermatological research 2006;298(7):353-6.
2006: Maeda Yutaka; Hwang-Verslues Wendy W; Wei Gang; Fukazawa Takuya; Durbin Mary L; Owen Laurie B; Liu Xuan; Sladek Frances M
Tumour suppressor p53 down-regulates the expression of the human hepatocyte nuclear factor 4alpha (HNF4alpha) gene.
The Biochemical journal 2006;400(2):303-13.
2006: Yang Nai-Ying; Pasquale Elena B; Owen Laurie B; Ethell Iryna M
The EphB4 receptor-tyrosine kinase promotes the migration of melanoma cells through Rho-mediated actin cytoskeleton reorganization.
The Journal of biological chemistry 2006;281(43):32574-86.
2006: Ma Lisa J; Guzmán Esther A; DeGuzman Ariel; Walter Barbara; Muller H Konrad; Walker Ameae M; Owen Laurie B
Unexpected effects of UVB in IL-10 transgenic mice: normalization of contact hypersensitivity response.
Archives of dermatological research 2006;297(9):417-20.
2005: Guzmán E A; Chen Y-H; Langowski J L; De Guzman A; Lo H-L; Walter B; Muller H K; Walker A M; Owen L B
Abrogation of delayed type hypersensitivity response to Candida albicans produced by a molecular mimic of phosphorylated prolactin.
Journal of neuroimmunology 2005;170(1-2):31-40.
2005: Lo Hsin-Lung; Nakajima Satoshi; Ma Lisa; Walter Barbara; Yasui Akira; Ethell Douglas W; Owen Laurie B
Differential biologic effects of CPD and 6-4PP UV-induced DNA damage on the induction of apoptosis and cell-cycle arrest.
BMC cancer 2005;5():135.
2004: Chandrasekar Bysani; Vemula Kirankumar; Surabhi Rama Mohan; Li-Weber Min; Owen-Schaub Laurie B; Jensen Liselotte E; Mummidi Srinivas
Activation of intrinsic and extrinsic proapoptotic signaling pathways in interleukin-18-mediated human cardiac endothelial cell death.
The Journal of biological chemistry 2004;279(19):20221-33.
2004: Fukazawa Takuya; Maeda Yutaka; Sladek Frances M; Owen-Schaub Laurie B
Development of a cancer-targeted tissue-specific promoter system.
Cancer research 2004;64(1):363-9.
2004: Hall Christopher L; Yao Mike; Hill Laurie L; Owen-Schaub Laurie B
Essential role for hematopoietic Fas ligand (FasL) in the suppression of melanoma lung metastasis revealed in bone marrow chimeric mice.
Clinical & experimental metastasis 2004;21(3):251-6.
2003: Guzman E; Langowski J L; Owen-Schaub L
Mad dogs, Englishmen and apoptosis: the role of cell death in UV-induced skin cancer.
Apoptosis : an international journal on programmed cell death 2003;8(4):315-25.
2003: Fukazawa Takuya; Walter Barbara; Owen-Schaub Laurie B
Adenoviral Bid overexpression induces caspase-dependent cleavage of truncated Bid and p53-independent apoptosis in human non-small cell lung cancers.
The Journal of biological chemistry 2003;278(28):25428-34.
2002: Owen-Schaub Laurie B
Fas function and tumor progression: use it and lose it.
Cancer cell 2002;2(2):95-6.
2001: Lafleur E A; Jia S F; Worth L L; Zhou Z; Owen-Schaub L B; Kleinerman E S
Interleukin (IL)-12 and IL-12 gene transfer up-regulate Fas expression in human osteosarcoma and breast cancer cells.
Cancer research 2001;61(10):4066-71.
2001: Owen-Schaub L
Soluble Fas and cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(5):1108-9.
2001: Ivanov V N; Bhoumik A; Krasilnikov M; Raz R; Owen-Schaub L B; Levy D; Horvath C M; Ronai Z
Cooperation between STAT3 and c-jun suppresses Fas transcription.
Molecular cell 2001;7(3):517-28.
2000: Ouhtit A; Gorny A; Muller H K; Hill L L; Owen-Schaub L; Ananthaswamy H N
Loss of Fas-ligand expression in mouse keratinocytes during UV carcinogenesis.
The American journal of pathology 2000;157(6):1975-81.
2000: Owen-Schaub L; Chan H; Cusack J C; Roth J; Hill L L
Fas and Fas ligand interactions in malignant disease.
International journal of oncology 2000;17(1):5-12.
2000: Watson V E; Hill L L; Owen-Schaub L B; Davis D W; McConkey D J; Jagannath C; Hunter R L; Actor J K
Apoptosis in mycobacterium tuberculosis infection in mice exhibiting varied immunopathology.
The Journal of pathology 2000;190(2):211-20.
1999: Hill L L; Ouhtit A; Loughlin S M; Kripke M L; Ananthaswamy H N; Owen-Schaub L B
Fas ligand: a sensor for DNA damage critical in skin cancer etiology.
Science (New York, N.Y.) 1999;285(5429):898-900.
1999: Ekmekcioglu S; Okcu M F; Colome-Grimmer M I; Owen-Schaub L; Buzaid A C; Grimm E A
Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10.
Melanoma research 1999;9(3):261-72.
1999: Fukazawa T; Fujiwara T; Morimoto Y; Shao J; Nishizaki M; Kadowaki Y; Hizuta A; Owen-Schaub L B; Roth J A; Tanaka N
Differential involvement of the CD95 (Fas/APO-1) receptor/ligand system on apoptosis induced by the wild-type p53 gene transfer in human cancer cells.
Oncogene 1999;18(13):2189-99.
1999: Hill L L; Shreedhar V K; Kripke M L; Owen-Schaub L B
A critical role for Fas ligand in the active suppression of systemic immune responses by ultraviolet radiation.
The Journal of experimental medicine 1999;189(8):1285-94.
1999: Chan H; Bartos D P; Owen-Schaub L B
Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment.
Molecular and cellular biology 1999;19(3):2098-108.
1998: Owen-Schaub L B; van Golen K L; Hill L L; Price J E
Fas and Fas ligand interactions suppress melanoma lung metastasis.
The Journal of experimental medicine 1998;188(9):1717-23.
1998: Kobayashi T; Ruan S; Jabbur J R; Consoli U; Clodi K; Shiku H; Owen-Schaub L B; Andreeff M; Reed J C; Zhang W
Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment.
Cell death and differentiation 1998;5(7):584-91.
1997: Munker R; Marini F; Jiang S; Savary C; Owen-Schaub L; Andreeff M
Expression of CD95(FAS) by gene transfer does not sensitize K562 to Fas-killing.
Hematology and cell therapy 1997;39(2):75-8.
1996: Midis G P; Shen Y; Owen-Schaub L B
Elevated soluble Fas (sFas) levels in nonhematopoietic human malignancy.
Cancer research 1996;56(17):3870-4.
1996: Munker R; Midis G; Owen-Schaub L; Andreff M
Soluble FAS (CD95) is not elevated in the serum of patients with myeloid leukemias, myeloproliferative and myelodysplastic syndromes.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1996;10(9):1531-3.
1996: Santee S M; Owen-Schaub L B
Human tumor necrosis factor receptor p75/80 (CD120b) gene structure and promoter characterization.
The Journal of biological chemistry 1996;271(35):21151-9.
1995: Owen-Schaub L B; Angelo L S; Radinsky R; Ware C F; Gesner T G; Bartos D P
Soluble Fas/APO-1 in tumor cells: a potential regulator of apoptosis?
Cancer letters 1995;94(1):1-8.
1995: Owen-Schaub L B; Zhang W; Cusack J C; Angelo L S; Santee S M; Fujiwara T; Roth J A; Deisseroth A B; Zhang W W; Kruzel E
Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression.
Molecular and cellular biology 1995;15(6):3032-40.
1995: Schmitt D A; Owen-Schaub L; Ullrich S E
Effect of IL-12 on immune suppression and suppressor cell induction by ultraviolet radiation.
Journal of immunology (Baltimore, Md. : 1950) 1995;154(10):5114-20.
1994: Fujiwara T; Grimm E A; Mukhopadhyay T; Zhang W W; Owen-Schaub L B; Roth J A
Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene.
Cancer research 1994;54(9):2287-91.
1994: Kilbourn R G; Owen-Schaub L B; Cromeens D M; Gross S S; Flaherty M J; Santee S M; Alak A M; Griffith O W
NG-methyl-L-arginine, an inhibitor of nitric oxide formation, reverses IL-2-mediated hypotension in dogs.
Journal of applied physiology (Bethesda, Md. : 1985) 1994;76(3):1130-7.
1994: Owen-Schaub L B; Radinsky R; Kruzel E; Berry K; Yonehara S
Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness.
Cancer research 1994;54(6):1580-6.
1994: Nishikawa K; Rotbein J; Vijjeswarapu D; Owen-Schaub L; Rosenblum M G; Donato N J
Positive and negative selection for tumor necrosis factor responsiveness reveals an inhibitory role for EGF receptor in TNF-induced antiproliferation.
Lymphokine and cytokine research 1994;13(1):37-45.
1994: Owen-Schaub L B; Santee S M; Winkelhake J L; Zimmerman R J
Role of tumor necrosis factor species in the sequence-dependent effects of interleukin-2--tumor necrosis factor immunotherapy in mice: implications for preclinical cytokine testing.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1994;15(1):1-10.
1993: Owen-Schaub L B; Meterissian S; Ford R J
Fas/APO-1 expression and function on malignant cells of hematologic and nonhematologic origin.
Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy 1993;14(3):234-41.
1993: Fujiwara T; Grimm E A; Mukhopadhyay T; Cai D W; Owen-Schaub L B; Roth J A
A retroviral wild-type p53 expression vector penetrates human lung cancer spheroids and inhibits growth by inducing apoptosis.
Cancer research 1993;53(18):4129-33.
1993: Aggarwal B B; Gadhia P K; Hopwood V L; Dave B J; Risin S; Owen-Schaub L; Pandita R; Pathak S
Induction of chromosomal rearrangement by tumor necrosis factors produced by primary B lymphoblastoid cells derived from cancer patients.
Lymphokine and cytokine research 1993;12(1):9-19.
1992: Lazenby A W; Roth J A; Owen-Schaub L B; Grimm E A
IL-1 synergy with IL-2 in the generation of lymphokine activated killer cells is mediated by TNF-alpha and beta (lymphotoxin).
Cytokine 1992;4(6):479-87.
1992: Owen-Schaub L B; Yonehara S; Crump W L; Grimm E A
DNA fragmentation and cell death is selectively triggered in activated human lymphocytes by Fas antigen engagement.
Cellular immunology 1992;140(1):197-205.
1991: Yang S C; Grimm E A; Parkinson D R; Carinhas J; Fry K D; Mendiguren-Rodriguez A; Licciardello J; Owen-Schaub L B; Hong W K; Roth J A
Clinical and immunomodulatory effects of combination immunotherapy with low-dose interleukin 2 and tumor necrosis factor alpha in patients with advanced non-small cell lung cancer: a phase I trial.
Cancer research 1991;51(14):3669-76.
1991: Grimm E A; Owen-Schaub L
The IL-2 mediated amplification of cellular cytotoxicity.
Journal of cellular biochemistry 1991;45(4):335-9.
1991: Owen-Schaub L B; de Mars M; Murphy E C; Grimm E A
IL-2 dose regulates TNF-alpha mRNA transcription and protein secretion in human peripheral blood lymphocytes.
Cellular immunology 1991;132(1):193-200.
1991: Grimm E A; Bruner J M; Carinhas J; Köppen J A; Loudon W G; Owen-Schaub L; Steck P A; Moser R P
Characterization of interleukin-2-initiated versus OKT3-initiated human tumor-infiltrating lymphocytes from glioblastoma multiforme: growth characteristics, cytolytic activity, and cell phenotype.
Cancer immunology, immunotherapy : CII 1991;32(6):391-9.
1990: Crump W L; Owen-Schaub L B; Grimm E A
Molecular identification of the human tumor necrosis factor receptor on interleukin-2-stimulated peripheral blood lymphocytes.
Cellular immunology 1990;131(1):150-8.
1990: Yang S C; Owen-Schaub L B; Roth J A; Grimm E A
Characterization of OKT3-initiated lymphokine-activated effectors expanded with interleukin 2 and tumor necrosis factor alpha.
Cancer research 1990;50(12):3526-32.
1990: Yang S C; Owen-Schaub L; Mendiguren-Rodriguez A; Grimm E A; Hong W K; Roth J A
Combination immunotherapy for non-small cell lung cancer. Results with interleukin-2 and tumor necrosis factor-alpha.
The Journal of thoracic and cardiovascular surgery 1990;99(1):8-12; discussion 12-3.
1990: Owen-Schaub L B; De Mars M; Murphy E C; Grimm E A
TNF-beta (lymphotoxin) strongly upregulates TNF-alpha gene expression in human peripheral blood lymphocytes.
Lymphokine research 1990;9(4):491-7.
1989: Owen-Schaub L B; Crump W L; Morin G I; Grimm E A
Regulation of lymphocyte tumor necrosis factor receptors by IL-2.
Journal of immunology (Baltimore, Md. : 1950) 1989;143(7):2236-41.
1989: Yagita M; Itoh K; Tsudo M; Schaub L B; Platsoucas C D; Balch C M; Grimm E A
Involvement of both Tac and non-Tac interleukin 2-binding peptides in the interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes.
Cancer research 1989;49(5):1154-9.
1989: Crump W L; Owen-Schaub L B; Grimm E A
Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells.
Cancer research 1989;49(1):149-53.
1989: Yang S C; Owen-Schaub L; Grimm E A; Roth J A
Induction of lymphokine-activated killer cytotoxicity with interleukin-2 and tumor necrosis factor-alpha against primary lung cancer targets.
Cancer immunology, immunotherapy : CII 1989;29(3):193-8.
1989: Owen-Schaub L B; Grimm E A
Lymphokine-activated killer lymphocytes: evidence for regulation of induction and function by multiple cytokines.
Immunology series 1989;48():19-35.
1988: Loudon W G; Abraham S R; Owen-Schaub L B; Hemingway L L; Hemstreet G P; DeBault L E
Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties.
Cancer research 1988;48(8):2184-92.
1988: Owen-Schaub L B; Gutterman J U; Grimm E A
Synergy of tumor necrosis factor and interleukin 2 in the activation of human cytotoxic lymphocytes: effect of tumor necrosis factor alpha and interleukin 2 in the generation of human lymphokine-activated killer cell cytotoxicity.
Cancer research 1988;48(4):788-92.
1988: Owen-Schaub L B; Loudon W G; Yagita M; Grimm E A
Functional differentiation of human lymphokine-activated killing (LAK) is distinct from expansion and involves dissimilar interleukin 2 receptors.
Cellular immunology 1988;111(1):235-46.
1988: Grimm E A; Crump W L; Durett A; Hester J P; Lagoo-Deenadalayan S; Owen-Schaub L B
TGF-beta inhibits the in vitro induction of lymphokine-activated killing activity.
Cancer immunology, immunotherapy : CII 1988;27(1):53-8.
1988: Grimm E A; Owen-Schaub L B; Loudon W G; Yagita M
Lymphokine-activated killer cells. Induction and function.
Annals of the New York Academy of Sciences 1988;532():380-6.
1987: Owen-Schaub L B; Hemstreet G P; Hemingway L L; Abraham S R; DeBault L E
Population dynamics of the murine lymphokine activated killer system: precursor frequency and kinetics of maturation and renewal.
Cell and tissue kinetics 1987;20(6):591-602.
1986: Owen-Schaub L B; Abraham S R; Hemstreet G P
Phenotypic characterization of murine lymphokine-activated killer cells.
Cellular immunology 1986;103(2):272-86.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Laurie Owen-Schaub

Research Profile (preview)

Chemicals & Drugs

Anatomy

Living Beings

Physiology

Disorders

Phenomena

Procedures

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Laurie Owen-Schaub (preview)

All Publications